Last Updated : August 20, 2024
Details
Generic Name:
daratumumab
Project Status:
Pending
Therapeutic Area:
Multiple myeloma, eligible for autologous stem cell transplant
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Darzalex SC
Project Line:
Reimbursement Review
Project Number:
PC0388-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Darzalex SC (daratumumab injection) is indicated in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Darzalex SC (daratumumab injection) is indicated in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 20, 2024